Champlain Investment Partners LLC Lowers Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Champlain Investment Partners LLC cut its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 10.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,547,004 shares of the company’s stock after selling 176,821 shares during the period. Champlain Investment Partners LLC’s holdings in Omnicell were worth $67,449,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in OMCL. Arizona State Retirement System grew its holdings in shares of Omnicell by 2.9% in the second quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock valued at $348,000 after purchasing an additional 357 shares in the last quarter. Diversified Trust Co grew its stake in shares of Omnicell by 3.3% in the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock worth $416,000 after acquiring an additional 494 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares during the period. Louisiana State Employees Retirement System raised its stake in shares of Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after acquiring an additional 600 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in Omnicell by 7.4% in the first quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock valued at $265,000 after purchasing an additional 626 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Trading Up 3.6 %

Shares of Omnicell stock opened at $45.69 on Friday. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74. The firm’s 50 day moving average is $44.22 and its two-hundred day moving average is $37.25.

Analyst Ratings Changes

Several brokerages have weighed in on OMCL. Bank of America restated a “neutral” rating and set a $57.00 price target (up previously from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays upped their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Benchmark reiterated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Wells Fargo & Company increased their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. Finally, StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Omnicell presently has an average rating of “Hold” and an average target price of $52.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.